基于人群数据的当代五级格里森分级系统验证
该基于人群的研究利用监测、流行病学和最终结果(SEER)数据库纳入2006年1月至2012年12月诊断的331320例有原发和继发格里森分型的患者,评估五级格里森分级组(GGG)系统对前列腺癌特异性死亡率(PCSM)的预测能力。采用Fine和Gray比例风险模型分析,发现GGG每升高一级PCSM风险约翻倍,且无论治疗类型或临床分期如何,模式相似。
要点
- GGG每升高一级,前列腺癌特异性死亡风险约翻倍。
- 接受根治性前列腺切除术者中,以GGG1为参照,GGG2的调整HR为1.13(95%CI 0.83-1.54),GGG3为1.87(95%CI 1.33-2.65),GGG4为5.03(95%CI 3.59-7.06),GGG5为10.92(95%CI 8.03-14.84)。
- 无论接受何种主要癌症治疗或临床分期如何,GGG系统均能较好预测PCSM。
核心结论
- 新的五级GGG系统无论治疗类型或诊断时临床分期如何,均能较好地预测PCSM,有助于指导治疗决策。
研究设计与样本
- 基于人群的研究,利用SEER数据库纳入331320例2006年1月至2012年12月诊断且有原发和继发格里森分型的前列腺癌患者。
主要发现
- GGG每升高一级,PCSM风险约翻倍。
- 接受根治性前列腺切除术者中,以GGG1(格里森评分≤6)为参照,GGG2的调整HR为1.13(95%CI 0.83-1.54),GGG3为1.87(95%CI 1.33-2.65),GGG4为5.03(95%CI 3.59-7.06),GGG5为10.92(95%CI 8.03-14.84)。
- 无论接受何种主要癌症治疗或临床分期如何,均观察到相似模式。
临床怎么用
- 作者认为新的五级GGG系统有助于指导治疗决策。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: This population-based study assesses whether a proposed five-tiered Gleason grade grouping (GGG) system predicts prostate cancer-specific mortality (PCSM). Using the Surveillance, Epidemiology, and End Results (SEER) database, we identified 331320 prostate cancer patients who had primary and secondary Gleason patterns diagnosed between January 2006 and December 2012. We used the Fine and Gray proportional hazards model for subdistributions and the corresponding cumulative incidence to quantify the risk of PCSM. We found that the risk of PCSM approximately doubled with each GGG increase. Among men who underwent radical prostatectomy and using GGG1 (Gleason score ≤6) as the reference group, the adjusted hazard ratio for PCSM was 1.13 (95% confidence interval [CI] 0.83-1.54) for GGG2, 1.87 (95% CI 1.33-2.65) for GGG3, 5.03 (95% CI 3.59-7.06) for GGG4, and 10.92 (CI 8.03-14.84) for GGG5. Similar patterns were observed regardless of the type of primary cancer treatment received or clinical stage. In summary, our study, with large, racially diverse populations that reflect real world experiences, demonstrates that the new five-tiered GGG system predicts PCSM well regardless of treatment received or clinical stage at diagnosis. PATIENT SUMMARY: In this report we examined prostate cancer mortality using the new five-tiered cancer grading system using data for a large US population. We found that the new five-tiered cancer grading system can predict prostate cancer-specific mortality well, regardless of the type of primary cancer treatment and clinical stage. We conclude that this new five-tiered cancer grading system is useful in guiding treatment decisions.
引用
- He J, Albertsen PC, Moore D, et al. Validation of a Contemporary Five-tiered Gleason Grade Grouping Using Population-based Data. Eur Urol. 2016. PMID: 27939073. doi:10.1016/j.eururo.2016.11.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。